Imagine a world where cancer is caught in its earliest stages, dramatically increasing survival rates. A new study suggests we might be closer to that reality than we think. Multi-cancer early detection (MCED) tests could potentially slash the number of late-stage cancer diagnoses by nearly half over a decade!
A groundbreaking microsimulation model explored the impact of annual MCED testing, and the results are incredibly promising. This model indicates that incorporating these tests into routine healthcare could significantly reduce the number of cancers diagnosed at stage IV – the most advanced and often most difficult to treat stage. The study found a potential 45% reduction in stage IV diagnoses compared to current standard care.
But here's where it gets interesting... The research team, led by Jagpreet Chhatwal, PhD, from Massachusetts General Hospital and Harvard Medical School, used a sophisticated model simulating 5 million U.S. adults aged 50 to 84. This simulation encompassed 14 different cancer types, and the data, published in the journal Cancer, revealed not only a decrease in late-stage diagnoses but also increases in earlier-stage detection: a 10% rise in stage I diagnoses, a 20% increase in stage II, and a 34% increase in stage III. The most significant decreases in stage IV cases were observed in lung, colorectal, and pancreatic cancers – often detected late due to a lack of effective early screening programs.
The researchers emphasized the potential of MCED testing to "substantially reduce stage IV cancer incidence, particularly for cancer types that lack routine screening programs." They also acknowledged the need for real-world validation but suggested that MCED testing could revolutionize cancer diagnosis and improve patient outcomes across various cancer types.
Why is this so important? Consider this: approximately half of all cancer cases in the United States are discovered at advanced stages. Currently, routine screening is only recommended for four cancer types: breast, cervical, colorectal, and lung. This means that roughly 70% of new cancer cases occur in types for which no routine screening is available. This is a huge gap that MCED tests could potentially fill.
How does this simulation model work? The researchers developed a Simulation Model for MCED (SiMCED), a complex, continuous-time, discrete-event microsimulation. This model incorporated 14 solid tumor types, representing approximately 80% of cancer incidence and mortality. These included breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, kidney, liver, lung, ovarian, pancreatic, prostate, and urinary bladder cancers.
The model was meticulously designed to replicate annual cancer incidence rates reported in the Surveillance, Epidemiology, and End Results (SEER) database from 2015 to 2021. The simulated cohort included 5 million adults aged 50 to 84, all cancer-free at the start and with demographic characteristics mirroring the 2015 U.S. population.
And this is the part most people miss... The model accounted for cancer diagnoses arising from standard-of-care procedures, such as routine screening, incidental detection, and symptomatic presentation, as well as annual MCED testing. The base case assumed 100% uptake and adherence to annual MCED testing, providing an optimistic, best-case scenario.
Let's dive deeper into the stage IV reductions. When broken down by cancer type, the data revealed some compelling patterns. Lung cancer saw the largest absolute reduction (400 fewer cases per 100,000), followed by colorectal cancer (96 fewer cases) and pancreatic cancer (89 fewer cases). Relative reductions were most pronounced in cervical cancer (83%), liver cancer (74%), and colorectal cancer (59%). Interestingly, when breast and prostate cancers, for which MCED sensitivities are relatively lower, were excluded from the analysis, the overall stage IV reduction jumped from 45% to 50%.
But here's where it gets controversial... Stage IV reduction was actually higher for cancers with recommended screening programs (51%) compared to those without (39%). This suggests that MCED testing could both enhance existing screening efforts and serve as a crucial primary detection method for cancers lacking dedicated screening tests. Does this mean we should prioritize improving existing screening programs before broadly implementing MCED tests? Or should we pursue both simultaneously?
The study also found a modest 2.8% increase in total diagnoses (241 additional diagnoses per 100,000). The researchers emphasized that this relatively small increase "mitigates concerns that MCED testing could lead to a surge in unnecessary cancer diagnoses and treatment," suggesting that "overdiagnosis may not be an issue with this [MCED] technology."
However, the authors also acknowledged several limitations. These included uncertainties surrounding epidemiological parameters like disease dwell times and unobserved incidence, potential discrepancies between controlled study conditions and real-world test performance, and the assumption that MCED availability wouldn't affect standard screening uptake. The model also limited individuals to developing only one cancer type per lifetime, potentially underestimating MCED's true benefit.
Despite these limitations, the study's conclusion is compelling: incorporating an annual MCED test into standard care could lead to substantial downstaging of cancer at diagnosis over a 10-year period, with a significant reduction in stage IV diagnoses. As the authors stated, "These findings have strong clinical implications because earlier stage diagnosis is associated with improved survival."
So, what do you think? Could MCED tests be a game-changer in the fight against cancer? Are the potential benefits worth the cost and potential risks of overdiagnosis and overtreatment? Should we focus on cancers without current screening options, or enhance existing screening programs? Share your thoughts and opinions in the comments below!
References
- Chhatwal J, Xiao J, ElHabr AK, et al. The impact of multicancer early detection tests on cancer stage shift: A 10‐year microsimulation model. Cancer. 2025;e70075. doi:10.1002/cncr.70075
- Crosby D, Bhatia S, Brindle KM, et al. Early detection of cancer. Science. 2022;375(6586):eaay9040. doi:10.1126/science.aay9040
- Cancer Screening Tests. Centers for Disease Control and Prevention. October 17, 2023. Accessed November 13, 2025. https:// www.cdc.gov/cancer/prevention/screening.html
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12‐49. doi:10.3322/caac.2182
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
